Create an Account
  1. Home
  2. Specialty
  3. General Ophthalmology

A Close-Up on Presbyopia: Growing Your Optometric Practice With the New Spectrum of Presbyopia Treatments

EME
Program Information
Take Pre-Test

The live program has concluded.


If you attended, please click on the "Take Post-Test" button to claim your credit. If you did not attend, please stay tuned for the archived version, which will be available soon for on-demand viewing.

Scroll back to top
Details

  • Overview

    Learn strategies to manage presbyopes from early to late stages of progression using new and emerging pharmaceutical treatments options as well as next-generation, presbyopia-correcting IOLs.


    Agenda: (all times CT)

    7:45 PM    In-Person Dinner Registration Reception   

    8:15 – 8:20 PM    Introduction – Marc R. Bloomenstein, OD, FAAO (Program Chair)

    8:20 – 8:35 PM    The Early Presbyope: Topical Presbyopia Treatments – Josh K. Johnston, OD, FAAO

    8:35 – 8:40 PM    Panel Discussion

    8:40 – 9:00 PM    The Cataract Patient: Addressing Co-Management of Expanding Patient Needs with Next Generation Presbyopia-Correcting IOLs – Cecelia C. Koetting, OD, FAAO, Dipl ABO

    9:00 – 9:05 PM    Panel Discussion

    9:05 – 9:25 PM    The Presbyopia Patient Journey: Keys for Patient Discussions – Selina R. McGee, OD, FAAO, Dipl ABO

    9:25 – 9:30 PM     Summary and Conclusions

     

    This activity is supported by unrestricted educational grants from Abbvie, Alcon, and Johnson & Johnson Vision.

     

  • Learning Objectives

    Upon completion of this activity, the participant should be able to:

    • Define the prevalence, etiology, and key characteristics of progression of presbyopia from early to late-stage patients
    • Outline strategies for finding, communicating with, and educating patients about presbyopia-correction clinical outcomes, costs, risks, and benefits, including quality-of-life and quality-of-vision considerations
    • Describe how the latest presbyopia-correcting IOL technologies, multifocal contact lenses, and pharmaceutical presbyopia treatments can address outcomes in a new group of presbyopia patients, including those with comorbid conditions

  • Accreditation

    Evolve Medical Education LLC (Evolve) is a COPE-accredited administrator. 

    This in-person symposium, COPE Activity Number 124036, is accredited by COPE for continuing education for optometrists for 1.25 hours.
    Course #: 78649-GO
    Activity #: 124036


    This virtual interactive symposium, COPE Activity Number 124035, is accredited by COPE for continuing education for optometrists for 1.25 hours.
    Course #: 78650-GO
    Activity #: 124035

    COPE advises optometrists to contact the State or Provincial Board where they are licensed for verification of what is acceptable for license renewal.
     

  • Participation Method

    In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

    Course Viewing Requirements

    Supported Browsers:
    Internet Explorer 11 for Windows
    Edge (recent versions; Chromium-based) for Windows
    Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
    Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
    Safari (recent versions) for Mac OSX, or iOS

    Hardware Requirements:
    4GB+ RAM
    Recommended internet speed 5Mbps+

     

  • Faculty and Disclosures

    Marc R. Bloomenstein, OD, FAAO

    Marc R. Bloomenstein, OD, FAAO

    Schwartz Laser Eye Center
    Director of Optometric Services
    Scottsdale, AZ

     

    Josh K. Johnston, OD, FAAO

    Josh K. Johnston, OD, FAAO

    Residency Director and Clinical Director
    Georgia Eye Partners
    Atlanta, GA

     

    Cecelia C. Koetting, OD, FAAO, Dipl ABO

    Cecelia C. Koetting, OD, FAAO, Dipl ABO

    Hines Sight
    Denver, CO

     

    Selina R. McGee, OD, FAAO, Dipl ABO

    Selina R. McGee, OD, FAAO, Dipl ABO

    Intrepid Eye Society Vice-President

    Oklahoma Association of Optometric Physicians-Past President

    Founder/CEO, BeSpoke Vision

    Edmond, OK

     

    DISCLOSURE POLICY
    It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.

    The following faculty/staff members have the following financial relationships with ineligible companies.

    Marc R. Bloomenstein, OD, FAAO, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Aerie Pharmaceuticals, Allergan, Azura, Bausch + Lomb, Johnson & Johnson Vision, Kala Pharmaceuticals, OcuSoft, Sight Sciences, Sun Pharmaceutical Industries, and Tarsus. Grant/Research Support: Sight Sciences. Speaker’s Bureau: Allergan, Bausch + Lomb, Johnson & Johnson Vision, Kala Pharmaceuticals, OysterPoint, RVL, Sight Sciences, and Sun Pharmaceutical Industries.

    Josh K. Johnston, OD, FAAO, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Allergan, Astareal, Avellino, BioTissue, Bruder, Carl Zeiss Meditec, Dompé, Glaukos, Horizon Therapeutics, Johnson & Johnson Vision, Kala Pharmaceuticals, Maxi Vision, Orasis, Oyster Point Pharma, Quidel, SeaGen, Sight Sciences, Sun Pharmaceutical Industries, Tarsus, and Visus. Grant/Research Support: Allergan and Tarsus. Speaker’s Bureau: Allergan, BioTissue, Glaukos, Kala Pharmaceuticals, Oyster Point Pharma, Quidel, Sight Sciences, and Sun Pharmaceutical Industries. 

    Cecelia C. Koetting, OD, FAAO, Dipl ABO, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon, Aldeyra, Allergan, Avellino, Bruder, Dompé, Eyevance, Glaukos, Kala Pharmaceuticals, Orasis, OysterPoint, RVL, and Thea. Grant/Research Support: Johnson & Johnson Vision. Speaker's Bureau: Alcon, Dompé, Eyevance, OysterPoint, and RVL.

    Selina R. McGee, OD, FAAO, Dipl ABO, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Allergan, Bruder, Cynosure, Dompé, Horizon Therapeutics, Kala Pharmaceuticals, Lumenis, Novartis, Optovue, Osmotica Pharmaceuticals, Science Based Health, Sun Pharmaceuticals, Tarsus, Thea, and Versant. Speaker's Bureau: Allergan, Dompé, Lumenis, and Optovue.

    The Evolve and The Fundingsland Group staff, planners, and reviewers have no financial relationships with ineligible companies.

     

  • Disclaimer

    OFF-LABEL STATEMENT
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER
    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, The Fundingsland Group, Abbvie, Alcon, or Johnson & Johnson Vision. 

     

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Expiration Date:

1.25 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

LIVE ON REACHMD RADIOBack to live radio
ReachMD Radio

Loading...

00:00
00:00
    Register

    We're glad to see you're enjoying Evolve Medical Education…
    but how about a more personalized experience?

    Register for free